Claims for Patent: 6,919,341

Summary for Patent: 6,919,341

Title:	Imidazopyrazines as cyclin dependent kinase inhibitors
Abstract:	In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
Inventor(s):	Paruch; Kamil (Garwood, NJ), Guzi; Timothy J. (Chatham, NJ), Dwyer; Michael P. (Scotch Plains, NJ), Doll; Ronald J. (Convent Station, NJ), Girijavallabhan; Viyyoor M. (Parsippany, NJ), Mallams; Alan (Hackettstwon, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	10/665,005
Patent Claims:	1. A compound represented by the structural formula: ##STR230## or a pharmaceutically acceptable salt or solvate thereof, wherein: R is selected from the group consisting of H, halogen, aryl, heteroaryl, cycloalkyl, arylalkyl, heterocyclyl, heterocyclylalkyl, alkenyl, alkynyl, --C(O)R.sup.7, ##STR231## wherein each of said aryl, heteroaryl, cycloalkyl, arylalkyl, alkenyl, heterocyclyl and the heterocyclyl moieties whose structures are shown immediately above for R can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, CF.sub.3, CN, --OCF.sub.3, --OR.sup.6, --C(O)R.sup.7, --NR.sup.5 R.sup.6, --C(O.sub.2)R.sup.8, --C(O)NR.sup.5 R.sup.6, --(CHR.sup.5).sub.n OR.sup.6, --SR.sup.6, --S(O.sub.2)R.sup.7, --S(O.sub.2)NR.sup.6 R.sup.8, --N(R.sup.5)S(O.sub.2)R.sup.7, --N(R.sup.5)C(O)R.sup.7 and --N(R.sup.5)C(O)NR.sup.5 R.sup.6 ; R.sup.1 is H, halogen or alkyl; R.sup.2 is selected from the group consisting of halogen, R.sup.9, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, alkenyl, alkynyl, cycloalkyl, --CF.sub.3, --C(O)R.sup.7, alkyl substituted with 1-6 R.sup.9 groups which groups can be the same or different with each R.sup.9 being independently selected, ##STR232## wherein each of said aryl, heteroaryl, arylalkyl and heterocyclyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, cycloalkyl, CF.sub.3, CN, --OCF.sub.3, --OR.sup.6, --C(O)R.sup.7, --NR.sup.5 R.sup.6, --C(O.sub.2)R.sup.6, --C(O)NR.sup.5 R.sup.6, --SR.sup.6, --S(O.sub.2)R.sup.7, --S(O.sub.2)NR.sup.5 R.sup.6, --N(R.sup.5)S(O.sub.2)R.sup.7, --N(R.sup.5)C(O)R.sup.7 and --N(R.sup.5)C(O)NR.sup.5 R.sup.6 ; R.sup.3 is selected from the group consisting of H, aryl, heteroaryl, heterocyclyl, --(CHR.sup.5).sub.n -aryl, --(CHR.sup.5).sub.n -heteroaryl, --(CHR.sup.5).sub.n --OR.sup.6, --S(O.sub.2)R.sup.6, --C(O)R.sup.6, --S(O.sub.2)NR.sup.5 R.sup.6, --C(O)OR.sup.6, --C(O)NR.sup.5 R.sup.6, cycloalkyl, --CH(aryl).sub.2, --(CH.sub.2).sub.m --NR.sup.8, --(CHR.sup.5).sub.n --CH(aryl).sub.2, ##STR233## wherein each of said aryl, heteroaryl and heterocyclyl can be substituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF.sub.3, CN, --OCF.sub.3, --OR.sup.5, --NR.sup.5 R.sup.6, --C(O.sub.2)R.sup.5, --C(O)NR.sup.5 R.sup.6, --SR.sup.6, --S(O.sub.2)R.sup.6, --S(O.sub.2)NR.sup.5 R.sup.6, --N(R.sup.5)S(O.sub.2)R.sup.7, --N(R.sup.5)C(O)R.sup.7 and --N(R.sup.5)C(O)NR.sup.5 R.sup.6 ; R.sup.5 is H or alkyl; R.sup.6 is selected from the group consisting of H, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein each of said alkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF.sub.3, OCF.sub.3, CN, --OR.sup.5, --NR.sup.5 R.sup.6, --CH.sub.2 OR.sup.5, --C(O.sub.2)R.sup.5, --C(O)NR.sup.5 R.sup.8, --SR.sup.6, --S(O.sub.2)R.sup.7, --S(O.sub.2)NR.sup.5 R.sup.6, --N(R.sup.5)S(O.sub.2)R.sup.7, --N(R.sup.5)C(O)R.sup.7 and --N(R.sup.5)C(O)NR.sup.5 R.sup.6 ; R.sup.7 is selected from the group consisting of alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein each of said alkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF.sub.3, OCF.sub.3, CN, --OR.sup.5, --NR.sup.6 R.sup.6, --CH.sub.2 OR.sup.5, --C(O.sub.2)R.sup.5, --C(O)NR.sup.5 R.sup.6, --SR.sup.6, --S(O.sub.2)R.sup.7, --S(O.sub.2)NR.sup.5 R.sup.6, --N(R.sup.5)S(O.sub.2)R.sup.7, --N(R.sup.5)C(O)R.sup.7 and --N(R.sup.5)C(O)NR.sup.5 R.sup.6 ; R.sup.8 is selected from the group consisting of R.sup.6, --C(O)NR.sup.5 R.sup.6, --S(O.sub.2)NR.sup.5 R.sup.6, --C(O)R.sup.7, --C(O.sub.2)R.sup.6, --S(O.sub.2)R.sup.7 and --(CH.sub.2)-aryl; R.sup.9 is selected from the group consisting of halogen, CN, NR.sup.5 R.sup.6, --C(O.sub.2)R.sup.6, --C(O)NR.sup.5 R.sup.6, --OR.sup.6, --C(O)R.sup.7, --SR.sup.6, --S(O.sub.2)R.sup.7, --S(O.sub.2)NR.sup.5 R.sup.6, --N(R.sup.5)S(O.sub.2)R.sup.7, --N(R.sup.5)C(O)R.sup.7 and --N(R.sup.5)C(O)NR.sup.5 R.sup.6 ; m is 0 to 4; n is 1-4; and p is 0-3. 2. The compound of claim 1, wherein R is selected from the group consisting of H, halogen, aryl, heteroaryl, alkenyl and --C(O)R.sup.7, wherein each of said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, CF.sub.3, CN, --OCF.sub.3, and --OR.sup.6 ; R.sup.1 is H or lower alkyl; R.sup.2 is selected from the group consisting of halogen, aryl, heteroaryl, alkenyl and --C(O)R.sup.7, wherein each of said aryl and heteroaryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, CF.sub.3, CN, --OCF.sub.3, and --OR.sup.6 ; R.sup.3 is selected from the group consisting of H, aryl, heteroaryl, --(CHR.sup.8).sub.n -aryl, --(CHR.sup.8).sub.n -heteroaryl, --(CHR.sup.8).sub.n --OR.sup.8, --C(O)R.sup.8, cycloalkyl, --CH(aryl).sub.2, ##STR234## wherein each of said aryl and heteroaryl can be substituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, CF.sub.3, CN, --C(O.sub.2)R.sup.5 and --S(O.sub.2)R.sup.6 ; R.sup.5 is H or lower alkyl; m is 0 to 2; and n is 1 or 2. 3. The compound of claim 2, wherein R is phenyl substituted with one or more moieties selected from the group consisting of F, Cl, Br and OCF.sub.3. 4. The compound of claim 2, wherein R.sup.2 is F, Cl, Br, I, ethenyl, or --C(CH.sub.3).sub.2 --OH. 5. The compound of claim 4, wherein R.sup.2 is Br, or I. 6. The compound of claim 2, wherein R.sup.3 is H, propan-1-ol-2-yl, phenyl, benzyl, (pyrid-2-yl)methyl, (pyrid-3-yl)methyl, (pyrid-4-yl)methyl, 2-[(pyrid-3-yl)]ethyl and 2-[(pyrid-4-yl)]ethyl wherein each of said phenyl (including phenyl of said benzyl) and pyridyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of F, Cl, Br, CF.sub.3, lower alkyl, --S(O.sub.2)CH.sub.3, methoxy and CN. 7. The compound of claim 6, wherein R.sup.3 is (pyrid-2-yl)methyl. 8. The compound of claim 6, wherein R.sup.3 is (pyrid-3-yl)methyl. 9. The compound of claim 6, wherein R.sup.3 is (pyrid-4-yl)methyl. 10. A compound of the formula: ##STR235## ##STR236## ##STR237## ##STR238## ##STR239## ##STR240## ##STR241## or a pharmaceutically acceptable salt or solvate thereof. 11. A compound of the formula: ##STR242## ##STR243## or a pharmaceutically acceptable salt or solvate thereof. 12. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 in combination with at least one pharmaceutically acceptable carrier. 13. The pharmaceutical composition of claim 12, additionally comprising one or more anti-cancer agents selected from the group consisting of a cytostatic agent, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine. 14. A method of inhibiting cyclin dependent kinases ("CDK2"), comprising administering a therapeutically effective amount of at least one compound of claim 1 to a patient in need of such inhibition. 15. A method of inhibiting cyclin dependent kinase CDK2, comprising administering to a mammal in need of such inhibition an amount of a first compound, which is a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof; and an amount of at least one second compound, said second compound being an anti-cancer agent; wherein the amounts of the first compound and said second compound result in a therapeutic effect. 16. The method of claim 15, further comprising radiation therapy. 17. The method of claim 15 wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, Iressa, Tarceva, antibodies to EGFR, Gleevec, Intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

Details for Patent 6,919,341

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2022-09-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2022-09-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2022-09-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2022-09-23